Literature DB >> 27430240

Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.

Rui Bao1, Xianqi Shui2, Jiong Hou1, Jinbao Li1, Xiaoming Deng1, Xiaoyan Zhu3, Tao Yang1.   

Abstract

The number of regulatory T cells (Treg cells) and the expression of ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1; also known as CD39) and 5'-ectonucleotidase (NT5E; also known as CD73) on the Treg cell surface are increased during sepsis. In this study, to determine the factors leading to the high expression of CD39 and CD73, and the regulation of the CD39/CD73/adenosine pathway in Treg cells under septic conditions, we constructed a mouse model of sepsis and separated the Treg cells using a flow cytometer. The Treg cells isolated from the peritoneal lavage and splenocytes of the mice were treated with adenosine or the specific adenosine A2A receptor agonist, CGS21680, and were transfected with specific siRNA targeting E2F transcription factor 1 (E2F-1) or cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB), which are predicted transcription regulatory factors of CD39 or CD73. The regulatory relationships among these factors were then determined by western blot analysis and dual-luciferase reporter assay. In addition, changes in adenosine metabolism were measured in the treated cells. The results revealed that adenosine and CGS21680 significantly upregulated CD39 and CD73 expression (P<0.01). E2F-1 and CREB induced CD39 and CD73 expression, and were upregulated by adenosine and CGS21680. Adenosine triphosphate (ATP) hydrolysis and adenosine generation were inhibited by the knockdown of E2F-1 or CREB, and were accelerated in the presence of CGS21680. Based on these results, it can be inferred that adenosine, the adenosine A2A receptor agonist, E2F-1 and CREB are the possible factors contributing to the high expression of CD39 and CD73 on the Treg cell surface during sepsis. Adenosine and its A2A receptor agonist served as the signal transducer factors of the CD39/CD73/adenosine pathway, accelerating adenosine generation. Our study may benefit further research on adenosine metabolism for the treatment of sepsis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27430240     DOI: 10.3892/ijmm.2016.2679

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  6 in total

1.  Is the regulation by miRNAs of NTPDase1 and ecto-5'-nucleotidase genes involved with the different profiles of breast cancer subtypes?

Authors:  Fernanda Cardoso da Silva; Angelo Borges de Melo Neto; Christina Aparecida Martins; Thaís Cunha de Sousa Cardoso; Matheus de Souza Gomes; Thaise Gonçalves de Araújo; Cristina Ribas Fürstenau
Journal:  Purinergic Signal       Date:  2021-11-05       Impact factor: 3.765

Review 2.  The Multifaceted Actions of CD73 During Development and Suppressive Actions of Regulatory T Cells.

Authors:  Meihong Da; Luxia Chen; Alexander Enk; Sabine Ring; Karsten Mahnke
Journal:  Front Immunol       Date:  2022-05-31       Impact factor: 8.786

Review 3.  Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.

Authors:  Yan Tie; Fan Tang; Yu-Quan Wei; Xia-Wei Wei
Journal:  J Hematol Oncol       Date:  2022-05-18       Impact factor: 23.168

4.  Identification of key pathogenic genes of sepsis based on the Gene Expression Omnibus database.

Authors:  Xinxing Lu; Lu Xue; Wenbin Sun; Jilu Ye; Zhiyun Zhu; Haifeng Mei
Journal:  Mol Med Rep       Date:  2017-12-12       Impact factor: 2.952

Review 5.  Immunometabolic Dysfunction of Natural Killer Cells Mediated by the Hypoxia-CD73 Axis in Solid Tumors.

Authors:  Andrea M Chambers; Sandro Matosevic
Journal:  Front Mol Biosci       Date:  2019-07-24

6.  Cell division cycle associated 8: A novel diagnostic and prognostic biomarker for hepatocellular carcinoma.

Authors:  Xiao-Han Cui; Qiu-Ju Peng; Ren-Zhi Li; Xia-Jie Lyu; Chun-Fu Zhu; Xi-Hu Qin
Journal:  J Cell Mol Med       Date:  2021-11-05       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.